Advertisement KineMed names new CEO - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

KineMed names new CEO

KineMed, a drug discovery and development company, has appointed Robert Stein as its new CEO and member of its board of directors.

Dr Stein currently serves on the president’s board of advisors for science and innovation for the University of California and is scientific advisor to Takeda San Diego.

David Fineman will continue in his capacity as chairman and president, and Marc Hellerstein will continue in his role as chairman of KineMed’s scientific advisory board and technical innovator of KineMed’s offerings.

Mr Fineman and Mr Hellerstein, cofounders of KineMed, said: “Bob has a significant record of accomplishment at the highest levels in the pharmaceutical industry. We are honored by Bob’s commitment to KineMed and look forward to working with him in the coming years.”